



ACICLOVIR

Read in conjunction with [Disclaimer](#)

! HIGH RISK Medication !

| Formulary: Restricted Requires Neonatologist/Microbiologist review within 24 hours of initiation | |
|--|---|
| Presentation | Vial (powder for reconstitution): 250 mg |
| Drug Class | Antiviral – guanine analogue |
| Indication | <ul style="list-style-type: none"> • Treatment or prophylaxis of herpes simplex virus (HSV) type I and II. • Treatment or prophylaxis of varicella zoster virus infection (VZV). |
| Special Considerations | <ul style="list-style-type: none"> • Duration should be discussed with clinical microbiologist. • Oral route is not recommended in neonates as absorption is erratic. Consult microbiologist regarding therapy for long term oral suppressive therapy. • Increased risk of impaired renal function in patients with pre-existing renal disease and dehydration, and with concomitant use of other nephrotoxic drugs. |
| Monitoring | <ul style="list-style-type: none"> • Urine output, renal and hepatic function. • Full Blood Count (FBC) • Aciclovir can crystalize out in the renal tubules and present as haematuria • IV site for phlebitis – prepare a more dilute infusion solution if phlebitis occurs |
| Compatibility | Fluids: Sodium Chloride 0.9%, Sodium Chloride 0.45%, Glucose 5% Refer to KEMH Neonatal Medication Guideline: Y-Site IV Compatibility in Neonates . |
| Incompatibility | Amino acid/glucose solution (TPN), adrenaline (epinephrine), caffeine citrate, cefepime, ciprofloxacin, dobutamine, dopamine, hydralazine, midazolam, paracetamol, phenylephrine, piperacillin/tazobactam (EDTA-free), vecuronium, verapamil. |
| Interactions | <ul style="list-style-type: none"> • Nephrotoxic drugs (concurrent use) e.g. gentamicin, furosemide. • Ceftriaxone (concurrent use) may cause renal impairment. |

| | |
|--------------------------------|--|
| Side effects | Common: diarrhoea, vomiting, encephalopathy, extravasation, injection site reactions, hypotension. |
| | Infrequent: agitation, oedema, constipation, rash, renal impairment. |
| | Rare: seizures, anaemia, neutropenia, leucopenia, thrombocytopenia, crystalluria, anorexia, hepatitis, urticaria, pruritis, photosensitivity, Stevens-Johnson Syndrome, toxic epidermal necrolysis, anaphylaxis. |
| Storage & Stability | <ul style="list-style-type: none"> • Store at room temperature, below 25°C. • Do NOT refrigerate (may result in crystallisation). • Discard the solution if visible turbidity or crystallisation appears. |

| INTRAVENOUS | Presentation (for IV use) | Vial (powder for reconstitution): 250 mg Available from CIVAS (KEMH Only): 5 mg/mL |   | | | | | | | | | |
|-----------------------------------|--|--|--|---------------------------|------|-----------|--------------------|----------|----------------|-----------------------------------|----------|---------------|
| | Dosage | Treatment or prophylaxis of HSV or VSV <table border="1" data-bbox="488 833 1310 1090"> <thead> <tr> <th>Corrected Gestational Age</th> <th>Dose</th> <th>Frequency</th> </tr> </thead> <tbody> <tr> <td>Less than 30 weeks</td> <td>20 mg/kg</td> <td>Every 12 hours</td> </tr> <tr> <td>Greater than or equal to 30 weeks</td> <td>20 mg/kg</td> <td>Every 8 hours</td> </tr> </tbody> </table> <ul style="list-style-type: none"> • Dose adjustment: <ul style="list-style-type: none"> ○ Renal impairment: dose adjustment is required. Consult microbiologist or neonatal pharmacist. | | Corrected Gestational Age | Dose | Frequency | Less than 30 weeks | 20 mg/kg | Every 12 hours | Greater than or equal to 30 weeks | 20 mg/kg | Every 8 hours |
| | Corrected Gestational Age | Dose | | Frequency | | | | | | | | |
| | Less than 30 weeks | 20 mg/kg | | Every 12 hours | | | | | | | | |
| Greater than or equal to 30 weeks | 20 mg/kg | Every 8 hours | | | | | | | | | | |
| Preparation | IV infusion: Step 1 Reconstitution: Add 10 mL of water for injections or sodium chloride 0.9% to a 250 mg vial. Step 2 Dilution: Draw up 50 mg (2 mL) and make up to 10 mL total volume with compatible fluid. Concentration is now equal to 5 mg/mL | | | | | | | | | | | |
| Administration | IV infusion: Infuse via syringe driver pump over 60 minutes. <ul style="list-style-type: none"> • Discard the solution if any visual turbidity or crystallisation occurs before or during administration. • Rapid rate of infusion may lead to renal tubular damage & impaired renal function. Use central line if available Aciclovir is highly alkaline and can cause severe extravasation injury (<i>Risk of phlebitis and extravasation increases at concentrations greater than 10 mg/mL</i>). <ul style="list-style-type: none"> • <u>Empirical therapy:</u> may be given via a peripheral line. • <u>Long term treatment:</u> consider giving via central line. | | | | | | | | | | | |

Related Policies, Procedures, and Guidelines

HDWA Mandatory Policies:

[MP 0131/20: WA High Risk Medication Policy](#)

Clinical Practice Guidelines:

[Neonatology – Herpes Simplex Virus \(HSV\); management of neonates born to HSV positive women](#)

[Neonatology – Neonatal Viral Infections](#)

References

Takemoto CK, Hodding JH, Kraus DM. Pediatric & neonatal dosage handbook with international trade names index : a universal resource for clinicians treating pediatric and neonatal patients. 23rd ed. Hudson (Ohio): Lexicomp; 2017. 2,401 p. 58



Truven Health Analytics. Acyclovir sodium. In: NeoFax [Internet]. Greenwood Village (CO): Truven Health Analytics; 2023 [cited 2023 Jun 27]. Available from: <https://neofax.micromedexsolutions.com/>

Society of Hospital Pharmacists of Australia. Aciclovir. In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2023 [cited 2023 Jun 27]. Available from: <http://aidh.hcn.com.au>

Neomed Formularies. Aciclovir. In: The Royal Hospital for Women [Internet]. [South Eastern Sydney, New South Wales; 2021 [cited 2023 Jun 27]. Available from: <https://www.seslhd.health.nsw.gov.au/royal-hospital-for-women/neomed-formularies>

Therapeutic Guidelines. Neonatal herpes simplex infection. In: eTG complete [Internet]. West Melbourne (Victoria); Therapeutic Guidelines; 2023 [cited 2023 Jun 27]. Available from: <https://tgldcpd.tg.org.au>

Document history

| | | | | | |
|--|--|----------------|--|--------------|------------|
| Keywords | Aciclovir, acyclovir, herpes simplex virus, HSV, varicella zoster virus, VZV | | | | |
| Document Owner: | Chief Pharmacist | | | | |
| Author/ Reviewer | KEMH & PCH Pharmacy/Neonatology Directorate | | | | |
| Version Info: | 4.0 – full review (October 2023) | | | | |
| Date First Issued: | 01/2001 | Last Reviewed: | 24/10/2023 | Review Date: | 24/10/2028 |
| Endorsed by: | Neonatal Directorate Management Group | | | Date: | |
| NSQHS Standards Applicable: | <input checked="" type="checkbox"/>  Std 1: Clinical Governance | | <input checked="" type="checkbox"/>  Std 4: Medication Safety | | |
| Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from WNHS HealthPoint. | | | | | |

This document can be made available in alternative formats on request for a person with a disability.